Ganswindt Ute, Paulsen Frank, Corvin Stefan, Eichhorn Kai, Glocker Stefan, Hundt Ilse, Birkner Mattias, Alber Markus, Anastasiadis Aristotelis, Stenzl Arnulf, Bares Roland, Budach Wilfried, Bamberg Michael, Belka Claus
Department of Radiation Oncology, University of Tübingen, Tübingen, Germany.
BMC Cancer. 2005 Jul 28;5:91. doi: 10.1186/1471-2407-5-91.
The RTOG 94-13 trial has provided evidence that patients with high risk prostate cancer benefit from an additional radiotherapy to the pelvic nodes combined with concomitant hormonal ablation. Since lymphatic drainage of the prostate is highly variable, the optimal target volume definition for the pelvic lymph nodes is problematic. To overcome this limitation, we tested the feasibility of an intensity modulated radiation therapy (IMRT) protocol, taking under consideration the individual pelvic sentinel node drainage pattern by SPECT functional imaging.
Patients with high risk prostate cancer were included. Sentinel nodes (SN) were localised 1.5-3 hours after injection of 250 MBq 99mTc-Nanocoll using a double-headed gamma camera with an integrated X-Ray device. All sentinel node localisations were included into the pelvic clinical target volume (CTV). Dose prescriptions were 50.4 Gy (5 x 1.8 Gy / week) to the pelvis and 70.0 Gy (5 x 2.0 Gy / week) to the prostate including the base of seminal vesicles or whole seminal vesicles. Patients were treated with IMRT. Furthermore a theoretical comparison between IMRT and a three-dimensional conformal technique was performed.
Since 08/2003 6 patients were treated with this protocol. All patients had detectable sentinel lymph nodes (total 29). 4 of 6 patients showed sentinel node localisations (total 10), that would not have been treated adequately with CT-based planning ('geographical miss') only. The most common localisation for a probable geographical miss was the perirectal area. The comparison between dose-volume-histograms of IMRT- and conventional CT-planning demonstrated clear superiority of IMRT when all sentinel lymph nodes were included. IMRT allowed a significantly better sparing of normal tissue and reduced volumes of small bowel, large bowel and rectum irradiated with critical doses. No gastrointestinal or genitourinary acute toxicity Grade 3 or 4 (RTOG) occurred.
IMRT based on sentinel lymph node identification is feasible and reduces the probability of a geographical miss. Furthermore, IMRT allows a pronounced sparing of normal tissue irradiation. Thus, the chosen approach will help to increase the curative potential of radiotherapy in high risk prostate cancer patients.
RTOG 94 - 13试验已提供证据表明,高危前列腺癌患者可从盆腔淋巴结额外放疗联合同步激素消融治疗中获益。由于前列腺的淋巴引流高度可变,盆腔淋巴结的最佳靶区定义存在问题。为克服这一局限性,我们通过SPECT功能成像考虑个体盆腔前哨淋巴结引流模式,测试了调强放射治疗(IMRT)方案的可行性。
纳入高危前列腺癌患者。注射250 MBq 99mTc - Nanocoll后1.5 - 3小时,使用带有集成X射线装置的双头γ相机定位前哨淋巴结(SN)。所有前哨淋巴结定位均纳入盆腔临床靶区(CTV)。盆腔剂量处方为50.4 Gy(5×1.8 Gy/周),前列腺(包括精囊底部或整个精囊)剂量处方为70.0 Gy(5×2.0 Gy/周)。患者接受IMRT治疗。此外,还对IMRT与三维适形技术进行了理论比较。
自2003年8月起,6例患者采用该方案治疗。所有患者均可检测到前哨淋巴结(共29个)。6例患者中有4例显示前哨淋巴结定位(共10个),仅基于CT的计划无法对其进行充分治疗(“几何遗漏”)。可能出现几何遗漏的最常见定位是直肠周围区域。IMRT与传统CT计划的剂量体积直方图比较表明,当纳入所有前哨淋巴结时,IMRT具有明显优势。IMRT能显著更好地保护正常组织,减少接受临界剂量照射的小肠、大肠和直肠体积。未发生3级或4级(RTOG)胃肠道或泌尿生殖系统急性毒性反应。
基于前哨淋巴结识别的IMRT可行,可降低几何遗漏的概率。此外,IMRT能显著减少正常组织受照剂量。因此,所采用的方法将有助于提高高危前列腺癌患者放疗的治愈潜力。